Trials / Recruiting
RecruitingNCT06855212
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous cell carcinoma (HNSCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemiplimab | Given by IV infusion. |
| DRUG | Cetuximab | Given by IV infusion. |
Timeline
- Start date
- 2025-02-26
- Primary completion
- 2028-03-01
- Completion
- 2028-03-01
- First posted
- 2025-03-03
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06855212. Inclusion in this directory is not an endorsement.